Tekmira on Track to Start Cancer Rx Trial Before Year-End; Cholesterol Drug Still On Hold
November 18, 2010
Tekmira on Track to Start Cancer Rx Trial Before Year-End; Cholesterol Drug Still On Hold
The company also said that it may begin another clinical trial of its cancer therapy in a different indication in collaboration with the National Cancer Institute.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tekmira Touts Advances with Lipid Nanoparticle Technology
March 31, 2011 / Gene Silencing News - With Alnylam Settlement Money in Hand, Tekmira Plans 'Aggressive' Pipeline Advancement
November 15, 2012 / Gene Silencing News - Tekmira Management Offers Pipeline Update, Reiterates Claim to Disputed Delivery Technology
March 29, 2012 / Gene Silencing News - Tekmira Says Pipeline on Track Heading into Q4; Holds Course on Alnylam Litigation
November 10, 2011 / Gene Silencing News - Tekmira Cleared to Begin Second Phase I Trial of siRNA Cancer Drug
August 11, 2011 / Gene Silencing News